Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation
- Roche Elecsys NfL aids in detection of disease activity in adults with Multiple Sclerosis supporting better disease management decisions
- Elecsys NfL offers a minimally invasive testing option that can provide rapid answers to patients and caregivers
- NfL has the potential to provide patient insights for other neurological conditions such as Alzheimer’s and Huntington’s diseases
Basel, 9 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The Elecsys NfL test is intended to be used as an aid in detection of disease activity in adults (18-55 years old) with Relapsing-Remitting Multiple Sclerosis (RRMS) or Secondary Progressive Multiple Sclerosis (SPMS), providing critical insights for disease management.
“Around 2.8 million people are estimated to live with Multiple Sclerosis1. After diagnosis, many face challenges with managing their disease due to significant gaps in access to testing. This can lead to missed opportunities to detect disease progression in support of treatment optimisation,” said Matt Sause, CEO of Roche Diagnostics. “We are excited about the potential Elecsys NfL has to improve outcomes for MS patients by offering a minimally invasive blood draw that can deliver rapid results.”
Approximately 85% of MS cases are RRMS patients.2 The majority of people diagnosed with RRMS eventually transition to SPMS, in which neurologic function worsens over time and disability increases. For patients with RRMS and SPMS, detection of disease activity is critically important in enabling them and their physicians to make the best possible decisions for the management of the disease.
Although the current spotlight for NfL’s intended use is Multiple Sclerosis, increases in NfL concentrations have been reported in individuals with other neurodegenerative diseases, such as Alzheimer’s and Huntington’s diseases and in indications beyond neurology.
Elecsys NfL has the potential to help laboratories to scale MS testing on widely available, fully automated and standardised Roche cobas instruments with the confidence of IVD quality, in a timely manner.
In July 2022, the FDA also granted Breakthrough Device Designation to Roche’s Elecsys Amyloid Plasma Panel, an innovative new solution to enable Alzheimer’s disease to be detected earlier. With Elecsys NfL receiving this designation, it is an important step as the organisation strengthens its diagnostics neurology portfolio to meet growing societal needs.
About Elecsys® NfL
Neurofilament Light Chain (NfL) is an abundant protein exclusively present in neurons and a sensitive indicator of neuroaxonal damage. Under normal conditions, NfL is released at low level from axons however, this rate increases with age and following neuroaxonal damage. Therefore, abnormal, elevated levels of NfL can be detected in cerebrospinal fluid and blood in various acute and chronic neurological disorders. Although the current spotlight for NfL’s intended use is multiple sclerosis, increases in NfL concentrations have been reported in individuals with traumatic brain injury, amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s disease, Huntington’s disease and other neurodegenerative diseases 3, but also in other indications beyond neurology.
Roche’s Elecsys NfL is intended to be used as an aid in detection of disease activity in adults (18-55 years old) with Relapsing-Remitting Multiple Sclerosis (RRMS) or Secondary Progressive Multiple Sclerosis (SPMS).
Once approved, broad global access to this testing will exist through the 75,000 Roche instruments currently available worldwide.
About the Breakthrough Device Designation
The Breakthrough Devices Program is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these medical devices.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
 Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec; 26 (14):1816-1821
 MS Society [Internet; cited 2023, Oct 25] Available from: https://www.mssociety.org.uk/about-ms/types-of-ms/relapsing-remitting-ms
 Mayo Clinic [Internet; cited 2023, Oct 25] Available from: https://www.mayocliniclabs.com/test-catalog/overview/616854#Clinical-and-Interpretive
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
|Hans Trees, PhD|
Phone: +41 79 407 72 58
Phone: +41 79 771 05 25
Phone: +44 797 32 72 915
Phone: +41 79 461 86 83
Phone: +41 79 327 54 74
Phone: +49 172 6367262
Phone: +41 79 205 27 03
Phone: +41 79 935 81 48
Roche Investor Relations
|Dr. Bruno Eschli |
Phone: +41 61 68-75284
|Dr. Sabine Borngräber|
Phone: +41 61 68-88027
|Dr. Birgit Masjost|
Phone: +41 61 68-84814
|Dr. Gerard Tobin |
Phone: +41 61 68-72942
Investor Relations North America
Phone: +1 650 225 3217
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Share buybacks in Spar Nord Bank – transactions in week 485.12.2023 08:43:31 CET | Press release
Company announcement no. 71 In company announcement no. 8 2023, Spar Nord announced a share buyback programme of up to DKK 300 million. The share buyback was initiated on 13 February 2023. The purpose of the share buyback is to reduce the bank’s share capital by the shares acquired under the programme, and the programme is executed pursuant to Regulation (EU) No 596/2014 of 16 April 2014 (“Market Abuse Regulation”). In week 48 the following transactions were made under the share buyback programme. Number of sharesAverage purchase priceTransaction value (DKK)Accumulated from from last announcement2,518,100273,572,59627 November 20238,000103.91831,28028 November 20238,000103.22825,76029 November 20238,000104.39835,12030 November 20237,000104.06728,42001 December 20237,000103.57724,990Total week 48 38,000 3,945,570 Total accumulated 2,556,100 277,518,166 Following the above transactions, Spar Nord holds a total of 2,734,657 treasury shares, equal to 2.27 % of the Bank’s share capital. Ple
Aktietilbagekøb i Spar Nord Bank – transaktioner i uge 485.12.2023 08:43:31 CET | pressemeddelelse
Selskabsmeddelelse nr. 71 Spar Nord offentliggjorde i selskabsmeddelelse nr. 8 2023 et aktietilbagekøbsprogram på op til 300 mio. kr. Aktietilbagekøbet blev indledt 13. februar 2023. Aktietilbagekøbet sker med henblik på at nedsætte bankens aktiekapital med de under programmet købte aktier, og foretages i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 (”Markedsmisbrugsforordningen”). Under aktietilbagekøbsprogrammet er der i uge 48 gennemført følgende transaktioner: Antal aktierGennemsnitlig købskursTransaktionsværdi (DKK)Akkumuleret fra sidste meddelelse2.518.100273.572.59627. november 20238.000103,91831.28028. november 20238.000103,22825.76029. november 20238.000104,39835.12030. november 20237.000104,06728.42001. december 20237.000103,57724.990I alt uge 48 38.000 3.945.570 I alt akkumuleret 2.556.100 277.518.166 Efter de foranstående transaktioner ejer Spar Nord i alt 2.734.657 egne aktier svarende til 2,27 pct. af bankens aktiekapital. Spørgsmål i forbindelse
Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme5.12.2023 08:32:38 CET | Press release
To Nasdaq Copenhagen Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme Nykredit Realkredit A/S publishes final terms for an issue of SEK 500,000,000 Senior Non-Preferred Floating Rate Notes due 2027, which are issued pursuant to Nykredit Realkredit A/S's and Nykredit Bank A/S’s €15,000,000,000 Euro Medium Term Note Programme dated 12 May 2023. The final terms dated 1 December 2023 and the EMTN Programme dated 12 May 2023 are available for download on Nykredit's website at nykredit.com/ir. Enquiries may be addressed to Nykredit Realkredit A/S, Group Treasury, Nicolaj Legind Jensen, Head of Group Treasury, tel +45 44 55 11 10, or Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Attachment New_final_terms_for_Euro_Medium_Term_Note_Programme_Nykredit_Realkredit_A_S_2023-12-05_EN
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities5.12.2023 08:30:00 CET | Press release
SIENA, Italy, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that its new GMP facility located in Rosia Siena, is now GMP certified. The certification was granted by the GMP MED office of the Agenzia Italiana del Farmaco (AIFA) following an inspection occurred in July 2023. AIFA confirmed that Philogen new facility complies with the requirements and guidelines of Good Manufacturing Practice outlined in the Directive 2003/94/EC issued by the European Parliament. In the European Union, national competent authorities - AIFA in Italy - are responsible for inspecting manufacturing sites based within their own territories. Sites located in one European Member State also benefit from mutual recognition agreements (MRAs) that the European Commission has signed with the authorities of the United States, Switzerland, Canada, Israel, Australia, Japan and New Zealand concerning the conformity assessment of medicinal products. Philogen plant in Rosia was designe
Equinor ASA: Share buy-back5.12.2023 08:00:00 CET | Press release
Please see below information about transactions made under the fourth tranche of the 2023 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR). Date on which the fourth tranche of the 2023 programme was announced: 27 October 2023. The duration of the fourth tranche of the 2023 programme: 30 October 2023 to no later than 29 January 2024. From 27 November to 1 December 2023, Equinor ASA has purchased a total of 1,478,000 own shares at the Oslo Stock Exchange at an average price of NOK 347.8907 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)27 November298,000351.8852104,861,789.6028 November290,000351.1603101,836,487.0029 November302,000345.0671104,210,264.2030 November296,000348.2593103,084,752.801 December292,000343.1135100,189,142.00Previously disclosed buy-backs under the fourth tranche of the 2023 programme 5,609,000360.82142,023,847,117.50Total buy-backs under fo